BioCryst stock price target raised to $15 by RBC on HAE acquisition
PositiveFinancial Markets

BioCryst Pharmaceuticals has received a positive boost as RBC has raised its stock price target to $15 following the company's recent acquisition related to hereditary angioedema (HAE). This adjustment reflects confidence in BioCryst's growth potential and strategic direction, which is significant for investors looking for promising opportunities in the biotech sector.
— Curated by the World Pulse Now AI Editorial System